MHLW Research Team Develops Universal Flu Vaccine
This article was originally published in PharmAsia News
Executive Summary
A research team at the Ministry of Health, Labor and Welfare announced Jan. 29 that it has developed a universal flu vaccine. Led by National Institute of Infectious Disease Chief Researcher Tetsuya Uchida, the team made the vaccine based on common protein found in three highly mutated flu virus types, H5N1, H1N1 and a Hong Kong type. The team confirmed efficacy of the vaccine through preclinical trials. The vaccine is estimated to take several years before it will be available to the public. (Click here for more - Japanese language
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.